Author

Gert De Hertogh

PHASE 2A PROOF OF CONCEPT PLACEBO CONTROLLED STUDY WITH ORAL ABX464 50MG QD IN ULCERATIVE COLITIS SHOWS ENDOSCOPIC IMPROVEMENT WITH LOSS OF MICROSCOPIC DISEASE ACTIVITY IN MOST ENDOSCOPIC RESPONDERS
PHASE 2A PROOF OF CONCEPT PLACEBO CONTROLLED STUDY WITH ORAL ABX464 50MG QD IN ULCERATIVE COLITIS SHOWS ENDOSCOPIC IMPROVEMENT WITH LOSS OF MICROSCOPIC DISEASE ACTIVITY IN MOST ENDOSCOPIC RESPONDERS

Gert De Hertogh  et al.

IMPACT OF MIRIKIZUMAB THERAPY ON HISTOLOGIC MEASURES OF INTESTINAL INFLAMMATION IN A PHASE 2 STUDY OF PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE
IMPACT OF MIRIKIZUMAB THERAPY ON HISTOLOGIC MEASURES OF INTESTINAL INFLAMMATION IN A PHASE 2 STUDY OF PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE

Gert De Hertogh  et al.

THE VARIABILITY IN THE DISTRIBUTION OF HISTOLOGICAL ACTIVITY IN COLONIC SEGMENTS IN PATIENTS WITH ULCERATIVE COLITIS AND THE IMPACT HEREOF ON THE DEVELOPMENT OF AI TOOLS
THE VARIABILITY IN THE DISTRIBUTION OF HISTOLOGICAL ACTIVITY IN COLONIC SEGMENTS IN PATIENTS WITH ULCERATIVE COLITIS AND THE IMPACT HEREOF ON THE DEVELOPMENT OF AI TOOLS

Gert De Hertogh  et al.

ENDOSCOPIC AND HISTOLOGIC REMISSION IN TOFACITINIB TREATED REFRACTORY MODERATE-TO-SEVERE PATIENTS WITH ULCERATIVE COLITIS: A PROSPECTIVE REAL-LIFE COHORT
ENDOSCOPIC AND HISTOLOGIC REMISSION IN TOFACITINIB TREATED REFRACTORY MODERATE-TO-SEVERE PATIENTS WITH ULCERATIVE COLITIS: A PROSPECTIVE REAL-LIFE COHORT

Gert De Hertogh  et al.

SCORING OF HISTOLOGICAL REMISSION IN ULCERATIVE COLITIS BASED ON AUTOMATED COMPUTER-AIDED ANALYSIS OF ENDOSCOPIC IMAGES OUTPERFORMS HUMAN SCORING
SCORING OF HISTOLOGICAL REMISSION IN ULCERATIVE COLITIS BASED ON AUTOMATED COMPUTER-AIDED ANALYSIS OF ENDOSCOPIC IMAGES OUTPERFORMS HUMAN SCORING

Gert De Hertogh  et al.

Item 1 - 5 / 5
1